Investigational Product Accountability

You are the clinical monitor who is conducting the closeout visit, and your review of the allocation of investigational product show that 10 pills of the investigational drug are missing. Post a comprehensive response to the following: • Is this failure in drug accountability (with 10 pills missing) a concern? Why or why not? • What actions could have been taken during the trial to reduce the risk of this occurring?